Search All UT System Experts

Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer

David M. O'Malley, Debra L. Richardson, Patrick S. Rheaume, Ritu Salani, Eric L. Eisenhauer, Georgia A. McCann, Jeffrey M. Fowler, Larry J. Copeland, David E. Cohn, Floor J. Backes

Research output: Contribution to journal › Article › peer-review

45 Scopus citations

Fingerprint

Dive into the research topics of 'Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences